Follow
Wee Joo Chng
Wee Joo Chng
Cancer Science Institute of Singapore
Verified email at nus.edu.sg
Title
Cited by
Cited by
Year
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ...
The lancet oncology 17 (8), e328-e346, 2016
25442016
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ...
leukemia 36 (7), 1703-1719, 2022
18452022
The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle, IBO Araujo, ...
Leukemia 36 (7), 1720-1748, 2022
16262022
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ...
Cancer cell 12 (2), 131-144, 2007
12212007
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study
SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ...
Leukemia 26 (1), 149-157, 2012
10092012
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label …
MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ...
The Lancet Oncology 17 (1), 27-38, 2016
9992016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ...
Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016
9552016
IMWG consensus on risk stratification in multiple myeloma
WJ Chng, A Dispenzieri, CS Chim, R Fonseca, H Goldschmidt, ...
Leukemia 28 (2), 269-277, 2014
6912014
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ...
Nature medicine 18 (4), 521-528, 2012
6652012
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, ...
The lancet oncology 18 (4), e206-e217, 2017
4892017
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
G Mulligan, C Mitsiades, B Bryant, F Zhan, WJ Chng, S Roels, E Koenig, ...
Blood 109 (8), 3177-3188, 2007
4652007
P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation
XL Li, J Zhou, ZR Chen, WJ Chng
World journal of gastroenterology: WJG 21 (1), 84, 2015
4492015
Genetic aberrations and survival in plasma cell leukemia
RE Tiedemann, N Gonzalez-Paz, RA Kyle, R Santana-Davila, ...
Leukemia 22 (5), 1044-1052, 2008
4462008
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
M Chesi, DF Robbiani, M Sebag, WJ Chng, M Affer, R Tiedemann, ...
Cancer cell 13 (2), 167-180, 2008
4442008
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
4392016
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
MA Dimopoulos, H Goldschmidt, R Niesvizky, D Joshua, WJ Chng, A Oriol, ...
The Lancet Oncology 18 (10), 1327-1337, 2017
4282017
Telomerase directly regulates NF-κB-dependent transcription
A Ghosh, G Saginc, SC Leow, E Khattar, EM Shin, TD Yan, M Wong, ...
Nature cell biology 14 (12), 1270-1281, 2012
3842012
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
SJ Kim, DH Yoon, A Jaccard, WJ Chng, ST Lim, H Hong, Y Park, ...
The lancet oncology 17 (3), 389-400, 2016
3562016
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ...
Leukemia 31 (11), 2443-2448, 2017
3262017
Management of treatment-emergent peripheral neuropathy in multiple myeloma
PG Richardson, M Delforge, M Beksaç, P Wen, JL Jongen, O Sezer, ...
Leukemia 26 (4), 595-608, 2012
3122012
The system can't perform the operation now. Try again later.
Articles 1–20